Table 2 . Study variables in Mg treated and placebo group after 3 months intervention.
| MgSO 4 group (n =25) | Placebo group (n = 22) | ||
| End | End | p | |
| Age (years) | ________ | ________ | ________ |
| Sex (male/female) | ________ | ________ | ________ |
| Duration of diabetes (years) | ________ | ________ | ________ |
| BMI (kg/m2) | 26.41 ± 3.29 | 27.28 ± 5.13 | Not significant |
| Systolic blood pressure ( mm Hg) | 102.8 ± 9.51 | 117.2 ± 3.48 | <0.001 |
| Diastolic blood pressure ( mm Hg) | 62.85 ± 7.55 | 70 ± 7.07 | <0.05 |
| Serum Mg (mg/dl) | 2.16 ± 0.36 | 2.23 ± 0.50 | Not significant |
| Urine Mg (mg/dl) | 5.99 ± 2 | 4.56 ± 1.72 | <0.05 |
| Calcium to magnesium ratio | 4.64 ± 1.46 | 5.21 ± 1.65 | Not significant |
| Fasting blood glucose (mg/dl) | 125.8 ± 6.52 | 136.5 ± 7.94 | <0.0001 |
| 2hr PP blood glucose (mg/dl) | 189.1 ± 60.05 | 247.8 ± 86.74 | <0.01 |
| HbA1C (%) | 7.90 ± 1.68 | 7.61 ± 1.59 | Not significant |
| HOMA-IR index | 5.01 ± 2.47 | 4.65 ± 3.48 | Not significant |
| Fasting plasma insulin (qIU/ml) | 15.90 ± 8.02 | 13.35 ± 11.53 | Not significant |
| Triglycerides (mg/dl) | 158.7 ± 77.16 | 175.5 ± 107.5 | Not significant |
| Total cholesterol (mg/dl) | 176.2 ± 48.33 | 182.7 ± 56.23 | Not significant |
| LDL cholesterol (mg/dl) | 93.63 ± 24.58 | 120.4 ± 34.86 | <0.01 |
| HDL cholesterol (mg/dl) | 41.7 ± 8.79 | 43.65 ± 11.20 | Not significant |
| Non HDL cholesterol (mg/dl) | 125.30 ± 23.19 | 152.16 ± 37.05 | <0.001 |
| Hemoglobin concentration (gr/dl) | 13.46 ± 1.51 | 13.18 ± 1.71 | Not significant |
| Aspartate transfrase (IU/ml) | 18.15 ± 10.40 | 24.92 ± 12.12 | Not significant |
| Alanin transfrase (IU/ml) | 22.30 ± 2.83 | 33.93 ± 5.70 | <0.05 |
| Metformin dosage ( mg ) | 1371.42 ± 625.21 | 1750 ± 379.77 | <0.01 |
| Glibenclamid dosage ( mg ) | 10.76 ± 7.10 | 13.31 ± 6.18 | Not significant |
| Enalapril dosage (mg) | 13 ± 4.6 | 23 ± 6.6 | <0.01 |
| Atorvastatin dosage (mg) | 15 ± 1.88 | 17.5 ± 3.65 | Not significant |
Data are means ± SD.